home   |   contact us   |   sitemap     

 
   about Formula Pharmaceuticals  technology  pipeline NewsCareers  
   
   
             
   
Overview

 


Management

 


Board of Directors


Advisory Committee

 


Scientific Advisory Board

 


Business Development  

 

 

 

 

BOARD OF DIRECTORS
   
MAURITS W. GEERLINGS President and Chief Executive Officer
MARTYN GREENACRE Director
GIORGIO MOSCONI Director
GIUSEPPE DASTOLI Director
PAOLO TANONI Director
DOMENICO MASTRANGELO Director
   

MAURITS W. GEERLINGS, M.D., M.B.A.
President and Chief Executive Officer

Dr. Geerlings co-founded Formula Pharmaceuticals in 2009 and has more than 18 years of biopharmaceutical experience including general management, business development, international operations, biotech start-up, financing, government affairs, academic research, and strategic planning. Previously, Dr. Geerlings was a co-founder and former Director and Chief Operating Officer of Actinium Pharmaceuticals, an oncology focused biotechnology company; lead business development at Infinity Pharmaceuticals, a publicly traded oncology focused company; and served as Vice President, Business Development at Prism Pharmaceuticals, a privately-held biopharmaceutical company focusing on acute care medicines. Prior to joining Prism Pharma, Dr. Geerlings led business development activities in a variety of therapeutic areas with a predominant focus on oncology at Cephalon Inc., Alexion Pharmaceuticals and the Ludwig Institute for Cancer Research. Dr. Geerlings earned his M.D. from The University of Utrecht, Faculty of Medicine, Utrecht, The Netherlands, and his M.B.A. from The George Washington University in Washington, DC. He holds an M.S. from the University of Utrecht, The Netherlands.

MARTYN GREENACRE, M.B.A.
Director

Mr. Greenacre served as Chairman of BMP Sunstone Corporation, a pharmaceutical company recently acquired by Sanofi-Aventis. Mr. Greenacre also has served since 2002 as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company. Previously, Mr. Greenacre served as Chief Executive Officer and Director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company, and as President, Chief Executive Officer and Director of Zynaxis Inc., a biopharmaceutical company. Mr. Greenacre was Chairman Europe, SmithKline Beecham Pharmaceutical Company. He joined SmithKline & French in 1973, where he held positions of increasing responsibility in its European organization. Mr. Greenacre has served on a number of start-up company Boards and currently serves on Acusphere, Inc. (a drug delivery company) and Curis, Inc. (a biotechnology company). He earned his M.B.A. and B.A. from Harvard University.

GIORGIO MOSCONI, M.D., Ph.D.
Director

Dr. Mosconi co-founded Formula Pharmaceuticals and brings more than 22 years of experience in the biopharmaceutical industry. He was also co-founder, President and Chief Operating Officer at ACUREON, a search fund supported by three major U.S. VCs. Prior to this, he served as Senior Vice President, Business Development, at Vicuron Pharmaceuticals, Inc. (acquired by Pfizer in 2005), the result of a merger between Biosearch Italia and Versicor Inc. Previously, Dr. Mosconi served as Vice President, Medical Affairs and Business Development at Biosearch Italia and as European Executive Director for R&D Anti-infectives and Immunology at Bristol-Myers-Squibb. Dr. Mosconi began his career at Marion Merrell Dow (now Sanofi-aventis) serving as Italian Medical Leader, Anti-infectives, and then transitioning to European Therapeutic Leader. He earned his M.D. from the Medical School University of Milan and his Ph.D. in ENT, head and neck surgery from the University of Milan. He holds a B.A. in chemistry.

GIUSEPPE DASTOLI, MD
Director

Dr. Giuseppe Dastoli has more than 25 years of operational experience within the pharmaceutical and biotech industry. He served as Therapeutic Area Head at Roche for Oncology and Hematology at Roche, and led new oncology product launch activities at BristolMeyersSquibb. He served as Vice President, Commercial Operations at Cell Therapeutics Europe, a hematologic oncology focused biotech company, and served as President and CEO of Eudax Srl, a life sciences oriented consulting firm. Presently, Dr. Dastoli leads product development activities at Fondazione M. Tettamanti, where Formula’s C.I.K. CAR program originated.

PAOLO TANONI, Esq.
Director

Mr. Paolo Tanoni has more than 30 years of experience in corporate, business and industrial law, both in Italy and internationally. He is founding Partner of HNF Avvocati, a Milan-based law firm specialized in, among others, corporate finance, M&A and private equity, debt restructuring and corporate restructuring, banking and corporate litigation. He currently holds positions in a number of Italian and international companies, investment funds and advisory firms: in particular, he is member of the board of directors of Ariston Thermo, Alberto Aspesi & Co., Echidna, Furla, New Energy Development Holding, Ethica Corporate Finance, and is a statutory auditor of Compar (Bata). Graduated in Law with Macerata University, Italy, he is a member of the Macerata Bar – Italy, and also admitted to the Italian Supreme Court and other Italian Higher Courts Bar.

DOMENICO MASTRANGELO, Esq.
Director

Mr. Domenico Mastrangelo has more than 20 years of experience in corporate, business and industrial law. He is a Partner of HNF Avvocati, where he focuses on M&A, debt restructuring, corporate reorganization, Private Equity, and corporate, general & commercial law. Graduated in Law maxima cum laude with Pavia University, Italy, he is a member of the Taranto Bar – Italy, and also admitted to the Italian Supreme Court and other Italian Higher Courts Bar. Mr. Domenico Mastrangelo is also a member of the International Bar Association and the TMA – Turnaround Management Association.